A Phase 2 interventional study of Candesartan 8mg and Candesartan 16mg in Essential Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-30.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.
Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 8th largest by planned enrollment, is one of 7 that started in 2014, is one of 4 in phase 2, and was the 17th registered.
480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18–75
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 456 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.
Median enrollment 314 across the 34 interventional studies. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical: 2 open now, 2 under way, 1 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, this one has the largest planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 2, and was the 12th registered.
Chong Kun Dang Pharmaceutical’s Essential Hypertension studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing amlodipine in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chong Kun Dang Pharmaceutical’s 18 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Candesartan 8mg + Amlodipine 5mg, po, q.d.
Drug: Candesartan 8mg · Drug: Amlodipine 5mg
Candesartan 8mg + Amlodipine 10mg, po, q.d.
Drug: Candesartan 8mg · Drug: Amlodipine 10mg
Candesartan 16mg + Amlodipine 5mg, po, q.d.
Drug: Candesartan 16mg · Drug: Amlodipine 5mg
Candesartan 16mg + Amlodipine 10mg, po, q.d.
Drug: Candesartan 16mg · Drug: Amlodipine 10mg
Candesartan 8mg, po, q.d.
Drug: Candesartan 8mg
Candesartan 16mg, po, q.d.
Drug: Candesartan 16mg
Amlodipine 5mg, po, q.d.
Drug: Amlodipine 5mg
Amlodipine 10mg, po, q.d.
Drug: Amlodipine 10mg
Once a day, 8 weeks
Once a day, 8 weeks
Once a day, 8 weeks
Once a day, 8 weeks
The mean change of sitDBP (sitting diastolic blood pressure)
Time frame: From baseline at week 8
The mean change of sitDBP
Time frame: From baseline at week 4 and week 8
The mean change of sitSBP
Time frame: From baseline at week 4 and 8
Responder rate: The change of sitDBP > 10mmHg, sitSBP > 20mmHg
Time frame: From baseline at week 4 and 8
Control rate: Patient achieving sitDBP < 90mmHg and sitSBP < 140mmHg
Time frame: At week 4 and 8
The record gives a start of Mar 2014, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Candesartan · Amlodipine
Chong Kun Dang Pharmaceutical →